32nd week of 2013 patent applcation highlights part 38 |
Patent application number | Title | Published |
20130202624 | HUMAN B1 CELLS AND USES THEREOF - The present invention is directed to isolated populations of human natural immunoglobulin-producing B1 lymphocytes, wherein the B1 lymphocytes display surface biomarkers CD20, CD43 and CD27 and are either CD11b+ or GD11b−. The present invention is also directed to a method of isolating human natural immunoglobulin-producing B1 lymphocytes from a blood sample comprising isolating B lymphocytes from the sample that express surface biomarkers CD20, CD43 and CD27, and, optionally, CD11b. In addition, the present invention is directed to a methods for diagnosing a B1 cell disorder in a patient, determining the prognosis of a patient having a B1 cell disorder, and treating a patient having a B1 cell disorder. | 2013-08-08 |
20130202625 | USE OF HUMAN ERYTHROCYTES FOR PREVENTION AND TREATMENT OF CANCER DISSEMINATION AND GROWTH - The technology relates in part to methods of preventing and treating diseases and conditions associated with cancer, including methods, compositions, and kits used for preventing and treating cancer dissemination and growth. | 2013-08-08 |
20130202626 | METHOD FOR PURIFYING ACTIVE POLYPEPTIDES OR IMMUNOCONJUGATES - The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. | 2013-08-08 |
20130202627 | USE OF FLAGELLINS FROM THE GENUS MARINOBACTER AS VACCINATION ADJUVANTS - Use of flagellins from the genus | 2013-08-08 |
20130202628 | PRODUCTION AND THERAPEUTIC USES OF TH1-LIKE REGULATORY T CELLS - A unique CD4 | 2013-08-08 |
20130202629 | USES OF PHOSPHOLIPID CONJUGATES OF SYNTHETIC TLR7 AGONISTS - The invention provides uses for phospholipid conjugates of TLR agonists, for instance in vaccines, and to prevent, inhibit or treat a variety of disorders including inflammation, cancer and pathogen, e.g., microbe, infection. | 2013-08-08 |
20130202630 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES TO VACCINES - The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions. | 2013-08-08 |
20130202631 | COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES, CONTAINING PLANT STEM CELL LINES DERIVED FROM THE CAMBIUM OF PANAX GINSENG INCLUDING MOUNTAIN GINSENG OR GINSENG AS ACTIVE INGREDIENT - The present invention relates to a composition for preventing or treating liver diseases, which contains, as an active ingredient, any one or more of a homogeneous cell line derived from the cambium of | 2013-08-08 |
20130202632 | MINIMAL MOTIFS OF LINEAR B-CELL EPITOPES IN L1 PROTEIN FROM HUMAN PAPILLOMAVIRUS TYPE 58 AND THEIR APPLICATIONS - Minimal Motifs of linear B-cell epitopes in L1 structure protein from human papillomavirus type 58 (HPV 58) and their applications are disclosed. Eighteen linear epitope motifs and their extended 8-mer peptides in the L1 protein from HPV 58 are described, which can be used as antigens separately or in combination to specifically detect the serum from subjects with HPV 58 infection, or to develop preventive or therapeutic multi-epitope peptide vaccines against HPV 58 by inducing humoral immunity. Of the eighteen B-cell epitope motifs, ten of them are 100% conservative and one is highly conservative among many homologous proteins of high-risk HPVs. They can be used as candidate “universal” epitopes to develop preventive or therapeutic HPV vaccines. The amino acid sequences of the epitope motifs and the 8-mer peptide formula of the invention are shown below in SEQ ID No. 1-2, 2B, 3, 3B, 4-18, 18B, 19, 19B, and 20-32. | 2013-08-08 |
20130202633 | DETERMINATION OF IMMUNOGENIC PEPTIDES IN LYSOSOMAL ENZYMES AND INDUCTION OF ORAL TOLERANCE - Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS. | 2013-08-08 |
20130202634 | Dengue Virus (DV) Polypeptide Sequences, T Cell Epitopes and Methods and Uses Thereof - Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8 | 2013-08-08 |
20130202635 | PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI - This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A | 2013-08-08 |
20130202636 | Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins - A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or “efficiency” groups. The invention also relates to methods for reducing muscle paralysis and other conditions that may be treated with a botulinum toxin, particularly paralysis of subcutaneous, and most particularly, facial, muscles, by topically applying an effective amount of the botulinum toxin and carrier, in conjunction, to the subject's skin or epithelium. Kits for administration are also described. | 2013-08-08 |
20130202637 | Dietary Supplements Including Ellagitannins and Ellagic Acid - A dietary supplement containing a source of ellagic acid, such as black raspberry seed powder, is combined with one or more of blue green algae, brown seaweed, phycocyanin and phenylathylemine. Additions of one or more vitamins and/or one or more minerals further improves the health enhancing benefits of the dietary supplement. | 2013-08-08 |
20130202638 | VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF - The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient. | 2013-08-08 |
20130202639 | Synthetic Herpes Simplex Viruses for Treatment of Cancers - New recombinant oncolytic viral vectors have been constructed based on a known herpes simplex virus-1 with a single 34.5 gene and a synctial mutation (called OncSyn (OS) virus), which was designed to be more immunogenic than the parental OS virus largely due to deletion of the viral gene viral host shutoff (vhs) gene (the “OSV” virus). In another embodiment, the OSV virus was constructed to constitutively express 15-PGDH (the “OSVP” virus), the principal enzyme responsible for degradation of PGE2. OSVP was shown to decrease both breast tumors and prostate cancer tumors in mice models. In addition, OSVP was shown to trigger substantial inflammatory cytokine production and pro mote anti-tumor immune responsiveness. These altered viruses, OSV and OSVP, can be used to treat various cancers including breast, prostate, liver, colon, and other tissues. Other exogenous genes can be added to either OSV or OSVP to improve the therapeutic response. | 2013-08-08 |
20130202640 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 2013-08-08 |
20130202641 | IMMUNOLOGY TREATMENT FOR BIOFILMS - The invention provides a composition for use in raising an immune response to | 2013-08-08 |
20130202642 | IMMUNOGENIC COMPOSITIONS AGAINST TUBERCULOSIS - Methods of preparing mutants of | 2013-08-08 |
20130202643 | Avirulent Salmonella Gallinarum Variants and Pharmaceutical Composition Using the Same - The present invention relates to avirulent | 2013-08-08 |
20130202644 | METHODS OF TREATING CANCER - The present invention relates to compositions and methods for treating an animal with a tumor or other metabolic disorder. In particular, the presently disclosed subject matter relates to methods of electroporating exosomes shed by tumors and by other metabolic disorders into immune cells such as dendritic cells and T cells. Administration of the electroporated immune cells to an animal with a tumor results in an increased immune response to the tumor and treatment of the tumor. | 2013-08-08 |
20130202645 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) - The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine. | 2013-08-08 |
20130202646 | COMPOSITIONS AND METHODS FOR MODULATING AUTOPHAGY - In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a Tat-Atg5K130R (inhibitor of autophagy) and a Tat-Beclin 1 (stimulant or activator of autophagy), and nucleic acids expressing them and methods for making and using them, e.g., to treat conditions and disorders responsive to autophagy modulation (e.g., where autophagy is dysregulated), including neurodegeneration, cystic fibrosis, cancer, heart failure, diabetes, obesity, sarcopenia, aging, ischemia/reperfusion, inflammatory disorders including Crohns, ulcerative colitis, biliary cirrhosis, lysosomal storage diseases, infectious diseases associated with intracellular pathogens including viruses, bacteria, and parasites such as Trypanosomes and malaria. | 2013-08-08 |
20130202647 | Chloroplast Expression of Membrane Proteins - Disclosed herein are chloroplast transformation vectors constructed to enable expression and hyperaccumulation of membrane proteins in chloroplasts. Another embodiment relates to plants transformed with such vectors. Another embodiment relates to seeds and other plant tissues transformed with such vectors. Another embodiment relates to a method of increasing expression of membrane proteins in chloroplasts including transforming a plant cell with vectors described herein. | 2013-08-08 |
20130202648 | Immunoregulator Compounds - The invention relates to sphingosine derivative compounds, like D-erythro-sphingosine | 2013-08-08 |
20130202649 | ACTIVATION OF INNATE IMMUNITY FOR NUCLEAR REPROGRAMMING OF SOMATIC CELLS - The nuclear reprogramming of somatic cells with non-integrating factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of toll-like receptors, e.g. TLR3. Somatic cells with activated innate immune responses can be reprogrammed to induced pluripotent cells or to transdifferentiated cells. | 2013-08-08 |
20130202650 | TOPICAL COMPOSITION COMPRISING A COMBINATION OF AT LEAST TWO PENETRATION ENHANCING AGENTS - The present invention relates to a composition for improved transdermal drug delivery comprising a drug, a combination of at least two penetration enhancing agents, wherein at least on the of the penetration enhancing agents is selected from the group consisting of esters of saturated or unsaturated fatty acids and lower alcohols, and iso-form alcohols; wherein at least one of the penetration enhancing agents is selected from the group consisting of aliphatic diols and triols; and wherein the components are present in a non-aqueous solvent system. A preferred topical composition comprises the active substance imiquimod and the penetration enhancing agents isoproply myristate and propylene glycol. | 2013-08-08 |
20130202651 | COMPOSITE VACCINE ADJUVANT - The invention provides a composite vaccine adjuvant, which is comprised of sodium ferulate and zinc hydroxide in a mass ratio of 10:1˜50:1. When the composite vaccine adjuvant and vaccine used in combination, the humoral immunity response is enhanced effectively, the enhanced effects is similar with aluminum adjuvant, superior to single sodium ferulate adjuvant and single zinc hydroxide adjuvant. It is not only atoxic, safety, but also reliable in the range of immune dose. The composite vaccine adjuvant with easily obtained and commercially available raw materials, is low cost, stable performance and simple preparation technology, which can be used as an adjuvant of hepatitis B vaccine, gene-engineered vaccine, virus vaccine and so on. | 2013-08-08 |
20130202652 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS - A targeting lipid can have the formula (I) in which T4 is a targeting moiety. The targeting moiety can be chosen to favor the lipid being localized with a desired organ, tissue, cell, cell type or subtype, or organelle. The targeting moiety can include, for example, transferrin, anisamide, an RGD peptide, prostate specific membrane antigen (PSMA), fucose, an antibody, or an aptamer. | 2013-08-08 |
20130202653 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINOPROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY - Compounds of Formulas 1 and 2 | 2013-08-08 |
20130202654 | Topical Foam Composition - A topical foam pharmaceutical composition for rectal administration comprising rifaximin in the form of nanosized particles is described. Also described is a method of making the composition and the use of the composition to as a medicament. | 2013-08-08 |
20130202655 | Vaccines, Methods of Administering Vaccines, Methods and Products for Treating and/or Delaying Onset of Dysplastic Lesions, and Wafers for Oral Administration - Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material. | 2013-08-08 |
20130202656 | SYSTEMS AND KITS FOR THE FABRICATION OF TISSUE PATCHES - Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. | 2013-08-08 |
20130202657 | FOAMS OR PARTICLES FOR APPLICATIONS SUCH AS DRUG DELIVERY - The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or particles containing pharmaceutically active agents. The foam may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foam or particle has an unexpectedly high specific surface area. A high specific surface area may, in some cases, facilitate delivery or release of the pharmaceutically active agent when the foam or particles made from the foam (e.g., by milling) are administered to a subject. The foam may also exhibit a relatively high loading of the pharmaceutically active agent. In some cases, the foam may be a microcellular foam. In one set of embodiments, the foam is created using a supercritical fluid, such as supercritical C02. For example, a precursor to the foam, containing a pharmaceutically active agent, may be mixed with a foaming agent, then the pressure decreased to cause the foaming agent to expand, thereby causing a foam to form. The foam may then be subsequently ground or milled, or otherwise processed to form particles. | 2013-08-08 |
20130202658 | Compositions Comprising Buprenorphine - This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof. | 2013-08-08 |
20130202659 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 2013-08-08 |
20130202660 | FUNCTIONAL NANOSTRUCTURED CHITOSAN COATINGS FOR MEDICAL INSTRUMENTS AND DEVICES - Disclosed herein is an approach for coating a biocompatible material, in particular chitosan, onto a surface in need thereof. This approach results in a coating that is highly uniform, even on irregular surfaces, and enables ready adjustment of the morphology of the coated material. A convenient means to add a functional property to the biocompatible material by incorporation of functional additives is also provided. | 2013-08-08 |
20130202661 | FORMULATIONS OF VILOXAZINE - Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed. | 2013-08-08 |
20130202662 | o/w/o EMULSION CONTAINING LIGNAN COMPOUNDS AND COMPOSITION CONTAINING THE SAME - An O/W/O emulsion composition having at least one of lignan-class compounds dissolved in an internal oil phase is disclosed. This composition can be produced by a process comprising the steps of 1) dissolving at least one of lignan-class compounds in oil or fat to prepare a lignan-class compound dissolving liquid; 2) emulsifying the lignan-class compound dissolving liquid in a water phase to form an O/W emulsion; and 3) further emulsifying the O/W emulsion in an oil phase to prepare an O/W/O emulsion. | 2013-08-08 |
20130202663 | REMEDY - It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated. | 2013-08-08 |
20130202664 | MEDICAL ADSORBENT AND METHOD FOR PRODUCING SAME - A medical adsorbent for oral administration that has low dosage and excellent adsorptive capacity and selective adsorption for toxins to be removed, and is also economical and environmentally friendly. The medical adsorbent comprises granular activated carbon that is activated carbon obtained by carbonization and activation of refined cellulose or regenerated cellulose, and having a mean pore diameter of 1.5 to 2.2 nm, a BET specific surface area of 700 to 3000 m | 2013-08-08 |
20130202665 | OILY SOLID COSMETIC - An oily solid cosmetic is capable of effectively diminishing morphological problems, such as vertical wrinkles, in particular on the lip, over a long period of time. The present invention provides an oily solid cosmetic which contains: (A) a plate-like composite powder presenting interference colors, (B) a spherical composite powder wherein the surface of a spherical powder having a refractive index of 1.40 to 1.60 is coated with a coating component having a refractive index of 2.00 to 2.90, and (C) 1 to 40% by mass of a semi-solid oil component. Preferably, the cosmetic of the present invention further contains (D) heavy isoparaffin. The cosmetic of the present invention is capable of diminishing vertical wrinkles, in particular on the lip, over a long period of time, and of maintaining a glossy lip. | 2013-08-08 |
20130202666 | HAIR TREATMENT COMPOSITION - An aerated composition comprising, surfactant aggregates, perfume and a hydrophobin. | 2013-08-08 |
20130202667 | HYDROGEL PARTICLE COATED WITH LIPID AND METHOD FOR MANUFACTURING SAME - The present invention relates to hydrogel particles coated with lipid, which are made from dispersing hydrogel particles in an organic solvent in which lipids are dissolved, and to a method for manufacturing same. Unlike the existing method for manufacturing hydrogel core vesicles, the present invention can effectively manufacture same by using an emulsification method, without involving the steps of chemical treatment of the surface of hydrogels or dilution, thereby facilitating mass production and preventing the decrease of drug encapsulation efficiency. The present method could be widely used for research on delivery carriers of oil/water-soluble active material or cell structure reproduction and more particularly, a keratinocyte mimetic of the present invention containing natural moisturizing factors can contain a large quantity of bound water for a long time, thereby exhibiting superior capability to retain moisture and moisturize, and providing a composition for an ingredient in cosmetics for moisturizing. | 2013-08-08 |
20130202668 | Personal Towelette with Cooling Composition for Relief of Heat Symptoms - A cooling composition impregnated on a personal towelette which provides a cooling sensation to the body when wiped across the skin. The application of the towelette containing the cooling composition reduces the symptoms of heat due to hot flashes due to menopause, physical exertion, or high temperatures. The composition provides effective cooling but is mild to the skin since it contains active ingredients in combination with skin soothing compounds. The cooling composition of the present invention is made of a combination of natural herbs and botanicals specifically selected to provide synergistic cooling effects. | 2013-08-08 |
20130202669 | ALBUMIN FIBERS AND FABRICS AND METHODS OF GENERATING AND USING SAME - Provided are method of generating a fiber from a globular protein such as albumin. Also provided are albumin fibers and fabrics and methods of using same for bonding a damaged tissue or for ex vivo or in vivo formation of a tissue. | 2013-08-08 |
20130202670 | BIOACTIVE ANTIBACTERIAL BONE GRAFT MATERIALS CONTAINING SILVER - The present invention generally relates to silver-containing bioactive antibacterial materials and composites that enhance bone growth while preventing surgical site infection. The present invention also relates to bioactive antibacterial materials and composites that include a bimodal bioactive glass particle size distribution. The bioactive antibacterial composite finds utility in a variety of clinical applications including spine and orthopaedic procedures. | 2013-08-08 |
20130202671 | PROCESS FOR PRODUCING MICROCAPSULE FORMULATION AND MICROCAPSULE FORMULATION PRODUCED BY SAME PROCESS - The present invention is intended to provide a technique for delaying timing for releasing an agricultural chemical compound from a microcapsule formulation which contains the agricultural chemical compound in at least one compound from the group of consisting of ester compounds and aromatic hydrocarbon compounds. A microcapsule formulation produced by the following process is more effectively controlled in release of an agricultural chemical compound therefrom, than any of the existing microcapsule formulations. This production process comprises the steps of
| 2013-08-08 |
20130202672 | FIBER-ASSEMBLED TISSUE CONSTRUCTS - The present invention relates to a fiber-assembled tissue construct comprising at least one sinusoid unit, the unit comprising at least two polymeric fibers arranged in a sinusoid structure and fused together, each of said fibers comprising a porous matrix supporting biological components encapsulated in the fiber, wherein the biological components are patterned in three-dimensions within the construct. | 2013-08-08 |
20130202673 | HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY - The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug. | 2013-08-08 |
20130202674 | TISSUE PATCH - Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. | 2013-08-08 |
20130202675 | SYSTEMS AND METHODS FOR THE FABRICATION OF TISSUE PATCHES - Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. | 2013-08-08 |
20130202676 | CROSS-LINKED DEHYDRATED PLACENTAL TISSUE GRAFTS AND METHODS FOR MAKING AND USING THE SAME - Described herein are tissue grafts produced by contacting dehydrated placental tissue grafts with a cross-linking agent. The tissue grafts described herein provide barrier and prevent the migration of a bioactive agent from the wound. Thus, the tissue grafts enhance wound healing while preventing the undesirable migration of a bioactive agent from the wound. Methods for making and using the cross-linked grafts are also described herein. | 2013-08-08 |
20130202677 | PATCH - Provided is a patch that ensures high storage stability of donepezil or a salt thereof and allows stable transdermal administration of the donepezil or salt thereof in an amount that provides a pharmaceutical effect. The patch includes a substrate | 2013-08-08 |
20130202678 | PUF-A AND RELATED COMPOUNDS FOR TREATMENT OF RETINOPATHIES AND SIGHT-THREATENING OPHTHALMOLOGIC DISORDERS - Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival, retrobulbar, periocular, suprachoroidal, or intraocular administration are provided. Methods for screening siRNA, RNAi and shRNA, small molecules and monoclonal antibodies that inhibit Puf-A target activity and reduce apoptosis are provided. | 2013-08-08 |
20130202679 | Targeted Particles Comprising Landscape Phage Fusion Proteins and Heterologous Nucleic Acid - Disclosed are targeted particles comprising or consisting of a plurality of landscape phage fusion proteins complexed with heterologous nucleic acid, the landscape phage fusion proteins displaying a heterologous peptide and the targeted particle binding specifically to a target site. The particles may be utilized in methods for modulating expression of genes in target cells. | 2013-08-08 |
20130202680 | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE BY AMYLOID BETA PEPTIDE AND SPHIN-GOSINE-1-PHOSPHATE - The invention provides compositions and methods for treatment of Alzheimer's disease. Such methods entail administering agents that induce a beneficial immune and therapeutic response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain preferred embodiments of such methods, a preferred agent is amyloid beta peptide in combination with Sphingosine-1-phosphate, preferably delivered in certain embodiments in a liposomal formulation. | 2013-08-08 |
20130202681 | LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE FOR MANAGEMENT OF CANCER AND DISRUPTION OF CANCER ENERGY CYCLES - A method of treatment of cancer with a formulation of liposomally encapsulated glutathione, that is preferably used orally, increases the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic “fuel supply” that supports cancer cells, and without which the cells can die out. The method prevents the oxidative stress that damages normal support cells such as stromal fibroblast cells. By blocking the “fuel supply,” the invention can protect, prevent and reverse these cells from the steps of autophagy and mitophagy, that results in the cells decreasing the normal production of ATP for energy and using aerobic glycolysis for energy production. The use of oral liposomally encapsulated glutathione will maintain the presence and normal function of caveolin in fibroblast and other cells, thus preventing their conversion to autophagic tumor stromal cells. | 2013-08-08 |
20130202682 | SYNTHETIC MATRIX VESICLES FOR BIOMIMETIC MINERALIZATION - Compositions of synthetic matrix vesicles with mineralization relevant ions which direct mineralization of a biomimetic mineral phase and methods for use thereof are provided. | 2013-08-08 |
20130202683 | TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY - The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent. | 2013-08-08 |
20130202684 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA - Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases. | 2013-08-08 |
20130202685 | Use of a histamine H4 antagonist for the treatment of post-operative adhesions - The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering a histamine H4 receptor antagonist, systemically, directly to tissue surfaces in the body cavity, or both, and to delivery vehicles and compositions suitable for use for local, non-systemic administration of a drug to the body and directly to tissue within a body cavity having been subjected to a surgical procedure. | 2013-08-08 |
20130202686 | LIPOSOME COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - A liposome composition into which a drug can be introduced in a high encapsulation amount, which has sustained release properties to such an extent that an effective concentration can be maintained at a clinically satisfactory level, and which is suitable for subcutaneous administration or the like. The liposome composition includes: a first liposome which has an outer membrane composed of a multilayered lipid bilayer; and a plurality of second liposomes which are accommodated in a first liposome inner region defined by the outer membrane and each of which has an outer membrane composed of a lipid bilayer. The lipid bilayer of the second liposomes can be multilayered. The liposome composition has second liposome inner regions each defined by the outer membrane of each of the second liposomes. An ion gradient is formed at least between each of the second liposome inner regions and the outside of the first liposome. | 2013-08-08 |
20130202687 | Lipid vectors delivering gene silencers - Lipid vector delivering gene silencers which vector carries on its external surface at least one recognizing molecule directed against a cellular target molecule. The recognizing molecule is directed against GD | 2013-08-08 |
20130202688 | DELAYED RELEASE ORAL DISINTEGRATING PHARMACEUTICAL COMPOSITIONS OF LANSOPRAZOLE - The present invention relates to delayed release oral disintegrating pharmaceutical compositions of lansoprazole or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. | 2013-08-08 |
20130202689 | NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS - A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid. | 2013-08-08 |
20130202690 | ENCAPSULATED PICOPLATIN - The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about 10 microns. The picoplatin particles are dispersed within the powder of the formulation which includes a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate and an effective amount of up to about 5 wt % of a lubricant. | 2013-08-08 |
20130202691 | MODIFIED STARCH DERIVATIVE-BASED MATRIX FOR COLON TARGETING - A controlled-release oral pharmaceutical composition of at least an active agent, including: a) a lipophilic matrix consisting of lipophilic compounds and/or amphiphilic compounds; and b) an hydrophilic matrix, wherein the hydrophilic matrix includes at least an indigestible polysaccharide, the active ingredient being dispersed in the lipophilic and/or the hydrophilic matrix. | 2013-08-08 |
20130202692 | ORGANIC COMPOUNDS - The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT | 2013-08-08 |
20130202693 | Oral Dosage Forms of Bendamustine - In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic hydrophilic surfactant. | 2013-08-08 |
20130202694 | Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed. | 2013-08-08 |
20130202695 | Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. | 2013-08-08 |
20130202696 | Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. | 2013-08-08 |
20130202697 | CHIMERIC SURFACE ACTIVE PROTEINS - The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein. The chimeric protein may only consist of the above mentioned core of (a) and (b), but may also be flanked by additional components of the core, i.e. (a) or (b) or by (an) additional complete core(s) (a) and (b). The present invention furthermore relates to a method of coating and/or impregnating a material, comprising contacting the material with the chimeric protein or the composition of the invention. | 2013-08-08 |
20130202698 | L-ORNIDAZOLE FORMULATIONS AND THEIR APPLICATIONS IN TREATMENT OF PARASITIC INFECTIONS - This invention relates to new methods of treating parasitic infections, such as trichomonas vaginalis infection and cecum amoeba infection, using L-enantiomer enriched ornidazole, in particular enantiomerically pure L-ornidazole, which provides benefits such as higher efficacy and lower toxicity to central nervous system over the existing racemic Ornidazole drug. New methods of synthesizing L- and D-enantiomers of Ornidazole in high purity and enantiomeric excess (ee), new formulations of the enantiomerically enriched L- or D-ornidazole, as well as their preparation processes and methods of use, are also disclosed. | 2013-08-08 |
20130202699 | PHOSPHATE BINDER FORMULATION FOR SIMPLE DOSING - The invention relates to a pharmaceutical composition in the form of pourable granules or a chewable tablet containing at least one phosphate binding substance and at least one effervescent agent. The composition may be taken orally without adding water. | 2013-08-08 |
20130202700 | RAPIDLY DISINTEGRATING COATED TABLETS - Coated dosage forms comprising a tablet core, preferably in compressed form, that has a coating over its exterior surface and one or more patterns debossed in the tablet surface are disclosed. Methods for manufacturing such dosage forms are also disclosed. | 2013-08-08 |
20130202701 | (1r,4r)-6'-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane-1,1'-pyrano[- 3,4,b]indol]-4-amine for Treating Fibromyalgia and Chronic Fatigue Syndrome - The invention relates to a pharmaceutical dosage form comprising (1r,4r)-6′-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro-[cyclohexane-1,1′-pyrano[3,4,b]-indol]-4-amine or a physiologically acceptable salt thereof, for use in the treatment of fibromyalgia or chronic fatigue syndrome. | 2013-08-08 |
20130202702 | ORAL FORMULATIONS - A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed. | 2013-08-08 |
20130202703 | METHOD FOR PRODUCING GARDENIA BLUE PIGMENT - Provided is a method for producing a gardenia blue pigment resistant to discoloration which may occur in colored sugar-coated food or pharmaceutical products. The method for producing such a gardenia blue pigment comprises performing membrane separation using a membrane (for example, an ultrafiltration membrane) with a molecular weight cut-off of 3000 Da or larger for removal of low-molecular compounds from a solution resulting from β-glucosidase treatment of an iridoid glycoside (for example, geniposide etc.) in the presence of a protein hydrolysate (for example, a casein protein hydrolysate), the iridoid glycoside being obtainable by extraction from fruits of | 2013-08-08 |
20130202704 | USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME - The invention relates to the use of mexiprostil in the treatment and/or prevention of inflammatory bowel disease and of irritable bowel syndrome, to the combinations of mexiprostil with other drugs, and also to a novel method for the synthesis of mexiprostil. | 2013-08-08 |
20130202705 | ALCOHOL-RESISTANT FORMULATIONS - This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance. | 2013-08-08 |
20130202706 | NANOSTRUCTURED ATORVASTATIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. | 2013-08-08 |
20130202707 | Controlled Delivery of TLR Agonists in Structural Polymeric Devices - The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents. | 2013-08-08 |
20130202708 | VIRAL PARTICLE RELEASED AFTER INFECTION OF MAMMALIAN CELLS BY HUMAN CYTOMEGALOVIRUS (HCMV) CONTAINING A FUSION PROTEIN AND USE THEREOF - The present invention is related to a viral particle released after infection of mammalian cells by human cytomegalovirus (HCMV), wherein a) the particle is surrounded by a lipid membrane in which viral glycoproteins are embedded, b) the particle contains neither viral DNA nor capsids; and c) the particle contains a fusion protein comprising one or more parts of the T-cell antigen pp65 and at least one heterologous peptide, and wherein the at least one heterologous peptide is inserted at amino acid position W175 or A534 of the amino acid sequence of the T-cell antigen pp65. | 2013-08-08 |
20130202709 | METHODS OF TREATMENT OF PANCREATIC CANCER - The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent. | 2013-08-08 |
20130202710 | PHARMACEUTICAL COMPOSITION FOR THE PROLONGED RELEASE OF TRIMETAZIDINE - Composition for the prolonged release of trimetazidine wherein the inner phase comprises trimetazidine and the outer layer comprises a retardant and an anti-agglomerant. | 2013-08-08 |
20130202711 | Substance-encapsulating vesicle and process for producing the same - Provided is a method for easily and efficiently producing encapsulated substance vesicles wherein a substance is encapsulated in the cavity of vesicles obtained by polymer self-assembly. Empty vesicles that have membranes comprising a first polymer that is a block copolymer with uncharged hydrophilic segments and a first kind of charged segments and a second polymer with a second kind of charged segments that carry a charge that is the opposite of said first kind of charged segments as well as spaces that are enclosed by said membranes are mixed in an aqueous medium with the substance that is to be encapsulated in the spaces. | 2013-08-08 |
20130202712 | Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease - The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and/or biodegradable polymeric carrier, and to the use of biocompatible and/or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional compartmentalized pharmaceutically active agent. | 2013-08-08 |
20130202713 | COATING OF PARTICLES COMPRISING A PHARMACEUTICALLY ACTIVE INGREDIENT WITH A CARBONATE SALT OR PHOSPHATE SALT - The present invention belongs to the field of pharmaceutical industry and relates to a process for coating a particle comprising a pharmaceutically active ingredient (API) comprising the steps of providing a composition comprising carbonate ions, phosphate ions, or a mixture thereof, providing a particle comprising an API, and precipitating a carbonate salt, a phosphate salt or a mixture thereof onto said particles. | 2013-08-08 |
20130202714 | MITE COMPOSITION, METHOD FOR REARING A PHYTOSEIID PREDATORY MITE SPECIES, AND USE OF THE COMPOSITION FOR CONTROLLING CROP PESTS - The present invention relates to a mite composition, the rearing thereof and to the use of the composition for controlling crop pests. The invention provides a mite composition comprising: a rearing population of a phytoseiid predatory mite species, a population of at least one species from the order Astigmata, and optionally a carrier, wherein the population of the species from the order Astigmata is not alive. In particular the population of the species from the order Astigmata is in fast frozen form. The composition is used for controlling crop pests, such as thrip species. The crops may be greenhouse grown crops and open field crops. | 2013-08-08 |
20130202715 | ALUMINOSILICATE GLASS FOR TOUCH SCREEN - An aluminosilicate glass for touch screens is provided. The glass includes, calculated based on weight percentage: SiO | 2013-08-08 |
20130202716 | Treatment of Cancer Using Hypoxia Activated Prodrugs - Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy. | 2013-08-08 |
20130202717 | MATERIALS AND METHODS FOR DIAGNOSING AND PREDICTING THE COURSE OF PROSTATE CANCER - Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples. High nuclear FOXA1 expression was seen in 19% of primary tumors and 89% of metastatic tumors (p<0.0001). FOXA1 expression correlated positively with tumor size, extra-prostatic extension, angiolymphatic invasion, AR and metastasis but did not correlate with age, tumor stage, Gleason score, presence of PIN or multifocality, seminal vesicle or perineural invasion and status of surgical excision margins. Expression of GATA-3 was not seen in either normal epithelium or tumor. High FOXA1 expression is associated with development of metastatic prostate cancer. Accordingly, FOXA1 expression can be used to classify patients at higher risk for metastases. | 2013-08-08 |
20130202718 | MONITORING IMMUNOGLOBULIN HEAVY CHAIN EVOLUTION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - The invention is directed to methods of monitoring B-cell lymphoid proliferative disorders, such as B-cell acute lymphoblastic leukemias, by measuring the presence, absence and/or levels of correlating, or index, clonotypes and related clonotypes that have evolved therefrom, for example, as part of the disease condition. In one aspect, such methods are implemented by generating sequencing-based clonotype profiles and determining frequencies of correlating, or index, clonotypes present, including new clonotypes that have evolved therefrom, particularly, in the case of B-cell ALL, by VH substitution. The invention also includes use of such monitoring information to modify treatment status of a patient. | 2013-08-08 |
20130202719 | STABILIZED CHLORITE SOLUTIONS IN COMBINATION WITH FLUROPYRIMIDINES FOR CANCER - Pharmaceutical compositions for treating neoplastic disorders and uses thereof are provided. Said pharmaceutical compositions comprise stabilized chlorite solutions (e.g. WFIO) and a fluoropyrimidine, 5-FU, or a 5-FU prodrug (e.g. capecitabine, doxifluridine, UFT, S-1, or BOF-A2). The use of the above stabilized chlorite solution in combination with a fluoropyrimidine dramatically improves the quality of life index (QOL) of a patient undergoing cancer chemotherapy. Cancers that can be treated include cancers of the pancreas, gastrointestinal, head, neck, and breast. | 2013-08-08 |
20130202720 | METHODS OF TREATING HEPATITIS - The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient. | 2013-08-08 |
20130202721 | SENSORS FOR DETECTING SUBSTANCES IN BODILY FLUIDS - A system is disclosed that extracts bodily fluid to a reaction chamber for monitoring a substance or property of the patient fluid. In one embodiment, a pump is used to advance the sample of bodily fluid through a filter to produce a filtrate. Another pump advances filtrate into the reaction chamber, while another pump advances reactant into the reaction chamber. A sensor in communication with the reaction chamber determines a concentration of nitric oxide or one of its metabolic products. Methods are also disclosed. | 2013-08-08 |
20130202722 | Treatment of Neurocutaneous Syndrome, Including Compositions, Methods and Uses Thereof - A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof. | 2013-08-08 |
20130202723 | METHOD OF PRODUCING A CHINESE HERBAL COMPOSITION FOR TREATING TERMINAL CANCER PATIENTS WITH CONSTIPATION - Constipation is a common and serious problem for terminal cancer patients, often resulting in deterioration of the overall condition of the patients and causing great anxiety in their family members. Terminal cancer patients, according to the principle of palliative care and the symptoms of pain, are usually given morphine-like analgesics orally or by injection to ease the pain, and are therefore very likely to suffer from constipation, poor appetite, bloating and other relevant symptoms. The Chinese herbal composition of rhubarb and licorice extracts presented in this study can notably improve the symptoms of constipation, poor appetite, and bloating, and these results are statistically significant. | 2013-08-08 |